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FOREWORD
Though maternal and neonatal health has attracted both national and global attention, the tragedy still
lies in the fact that most of the causes of these deaths are not only treatable but largely preventable. As
part of our response at the Federal Ministry of Health (FMOH), we have developed the Integrated
Maternal Newborn and Child Health Strategy (IMNCH), as a national platform for all the concerted
efforts towards the rapid attainment of the Millennium Development Goals 4 and 5 by 2015.

The development of these training manuals (trainer and trainee's versions) is in line with the strategic
objectives 1 and 2 of the IMNCH Strategy. This will provide hands-on, detailed, descriptive and
practical instructions and tips necessary to respond to obstetric emergencies (severe pre-eclampsia
and eclampsia) that needlessly kill our women and children. These documents are integral part of the
collaborative efforts between FMOH and the MacArthur Foundation to scale up the use of
Magnesium sulphate in the management of severe pre-eclampsia and eclampsia in health facilities in
Nigeria. It is a two-year project involving all the 36 states and FCT.

Magnesium sulphate since the Collaborative Eclampsia Trial and the Magpie Trial has been
established as the gold standard in the management of severe pre-eclampsia and eclampsia but lack of
knowledge and necessary skill have been identified as some of the factors responsible for its limited
use in Nigeria. Thus with this manual the quality of health care delivery at the facilities will be greatly
improved because it will fill the critical knowledge gap both in training and practice with respect to
the management of severe pre-eclampsia and eclampsia.

It is my sincere hope and expectation that the drug and the standard care with the help of this manual
are made available to all the appropriate health facilities, training institutions and other stakeholders
throughout Nigeria to reduce the morbidity and mortality associated with preeclampsia/eclampsia.

Prof. Babatunde Osotimehin,
OON Honourable Minister of Health
November, 2009
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LIST OF ABBREVIATIONS
ALT

Alanine Transaminase

ANC

Ante Natal Care

AST

Aspartate Transaminase

ARDS

Adult Respiratory Distress Syndrome

BP

Blood Pressure

FHR

Fetal Heart Rate

FMOH

Federal Ministry Of Health

HELLPS

Hamolysis, elevated liver enzymes, low platelets

IM

Intra Muscular

IUFD

Intra-Uterine Foetal Death

IUGR

Intra-Uterine Growth Restriction

IV

Intravenous

MgSo4

Magnesium Sulphate

NHDS

National Health and Demographic survey

SOGON

Society of gynaecology and obstetrics of Nigeria

WHO

World Health Organization
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MODULE 1

SESSION ONE:
Definition & Classification of Hypertensive Disorders of Pregnancy
OBJECTIVES
At the end of this session participants will be able to:
1. Define the various types of hypertensive disorders of pregnancy
2. Classify hypertensive disorders of pregnancy

METHODOLOGY
•
Lectures
•
Discussions
•
Brainstorming
RESOURCES
•
Obstetrics text books
•
Flip charts & markers
•
Posters
•
WHO educational materials
DURATION
30 minutes
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CONTENT
A. DEFINITIONS

1. Hypertension in pregnancy can be defined as a blood pressure of ≥140/90 mmHg
measured on 2 separate occasions more than 6 hours apart OR a single reading at any
stage of pregnancy of systolic of ≥160mmHg or a diastolic of ≥110mmHg

2. Hypertension in pregnancy is also defined as an increase of at least 30mmHg systolic or
15mmHg diastolic over the booking blood pressure in the first half of pregnancy
* In our environment where majority of women register for antenatal care in the second half of
pregnancy, definition (1) is more practicable and therefore should be considered as the thumb
rule.

B.

CLASSIFICATION

No.
1.

Hypertensive Disorder of Pregnancy
Pregnancy-induced Hypertension (Gestational hypertension)
Pre-eclampsia

2.

3.
4.

I.
II.

Mild pre-eclmapsia
Severe Pre-eclampsia

Chronic Hypertension in pregnancy
Chronic hypertension with super-imposed pre-eclampsia

•
Pregnancy-induced hypertension (Gestational hypertension)
Pregnancy-induced hypertension is defined as hypertension as hypertension in the second
half of pregnancy (20 weeks and above) without proteinuria

1. Pre-eclampsia
Pre-eclampsia defined as hypertension in the second half of pregnancy (20 weeks and above)
associated with proteinuria (≥300mg/dL) in a patient not previously hypertensive or
proteinuric. There may or may not be pedal oedema.
2. Mild Pre-eclampsia
Mild pre-eclamspsia is when systolic blood pressure is between 140-160mmHg and a
diastolic blood pressure of between 90-100mmHg with proteinuria of +2 or less.
3. Severe Pre-eclampsia
Severe pre-eclampsia is when the systolic blood pressure is greater than 160 and a diastolic
BP of 100mmHg with proteinuria of 3+ (5g/24 hr urine). There are also neurological or
biochemical changes that can suggest severe disease. The appearance of symptoms like
headache, blurring of vision, vomiting or epigastric pain also suggest severe pre-eclampsia.
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Chronic Hypertension
•
Chronic hypertension is pre-existing hypertension or hypertension diagnosed in the first
half of pregnancy.
Chronic Hypertension with super-imposed pre-eclampsia
If pre-existing hypertension or hypertension diagnosed in the first half of pregnancy is
associated with proteinuria and other features of pre-eclampsia in the second half of
pregnancy, the condition is termed chronic hypertension with super-imposed pre-eclampsia
•
Eclampsia
Eclampsia is the occurrence of generalised tonic-clonic convulsions in a patient with preeclampsia in the absence of a neurological disease. It can be ante-partum eclampsia, intrapartum eclampsia or post-partum eclampsia. The intra-partum type is the most common in
Nigeria.
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SESSION 2
EPIDEMIOLOGY & IMPACT OF PRE-CLAMPSIA/ECLAMPSIA
ON MATERNAL MORTALITY IN NIGERIA

OBJECTIVES
At the end of this session participants will be:
1. Know the predisposing to pre-eclampsia/eclmapsia
2. Know the contribution of pre-eclampsia/eclampsia to maternal mortality
3. Discuss the socio-cultural and health system factors contributing to the high case fatality
rates in pre-eclampsia and eclampsia in Nigeria
METHODOLOGY
•
Brainstorming
•
Assignment or group activity
•
Lectures/discussions
RESOURCE
•
Flip charts
•
Fact sheets
•
Centre for reproductive right
•
Report on broken promise
•
FMoH maternal mortality final report
•
SOGON report on maternal mortality
DURATION
30 minutes
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CONTENT
A. INCIDENCE
Hypertensive disorders complicate 15% of pregnancies. Pre-eclampsia/eclampsia is the most
important type of hypertensive disorders in pregnancy in terms of incidence, morbidity and
mortality. While the incidence of pre-eclampsia is relatively constant world wide, the incidence of
eclampsia is higher in developing countries. The incidence of eclampsia in developing countries
varies from 10 to 50 per 1,000 deliveries (1-5%).
B. EPIDEMIOLOGY
Pre-eclampsia/Eclampsia as observed world-wide is largely a disease of primigravidity. In
Nigeria, over 80% of patients with eclampsia are primigravidae. In northern Nigeria, probably
because of the culture of early marriage. Majority of these primigravidae are teenagers
(<19years).
Other predisposing factors include lack of poor access to antenatal care, past history of
pregnancy-induced hypertension, positive family history of hypertension, multiple pregnancy,
molar pregnancy, diabetes mellitus and renal diseases
C. MATERNAL MORTALITY
Both pre-eclampsia and eclampsia cause maternal deaths. In developed countries, severe preeclampsia accounts for 1-2% of maternal deaths. In developing countries, severe preeclampsia/eclampsia account for >10% of maternal mortality. In some areas of sub-Saharan
Africa for example Northern Nigeria, eclampsia account for up to 40% of maternal deaths.
Contributing factors to the high maternal mortality include lack of ante-natal care, late
presentation and weak health system leading to poor quality emergency obstetric care.

Social contributory factors to maternal death include poverty, poor reproductive health careseeking behaviour, cultural perception of eclampsia and lack of access to quality maternal
services including intra-partum care.
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DIAGNOSIS OF PRE-ECLAMPSIA/ECLAMPSIA
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TREATMENT OF
ECLAMPSIA
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SESSION 1
DIAGNOSIS OF PRE-ECLAMPSIA
OBJECTIVES
At the end of this session participants will be:
1. Know how to pre-eclampsia
2. Know the symptoms and signs of pre-eclampsia
3. Know the preventive measures for pre-eclampsia
METHODOLOGY
•
Lecture
•
Discussions
•
Brainstorming
•
Practical demonstration
RESOURCE
•
Flip chart/stand and markers
•
Sphygmomanometer/stethoscopes
•
Power point projector
•
Text books
Instructional materials

DURATION
45 minutes

Trainee's Notes:
If we have ten women with mild pre-eclampsia, how many of them would present with
symptoms?
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CONTENT
DEFINITION/Diagnosis
Pre-eclampsia is defined as elevated or high blood pressure in pregnancy after 20weeks of
gestation measured on two occasions at least four hours apart with proteinuria.
Hypertension is defined as a rise in blood pressure of 140/90mmHg or more in a previously
normotensive woman.
Proteinuria is the occurrence of at least 300 milligrams of protein per litre of urine in at least two
random clean catch specimens at least 6 hours apart (the urine should be clean catch midstream
specimen to avoid contamination by vaginal secretions).
Pre eclampsia is usually without any symptoms until the condition deteriorates. The insidious
nature of the disease makes it life threatening. Often mild pre-eclampsia can progress to severe
pre-eclampsia or even eclampsia without warning. Pre eclampsia is best detected in its earliest
forms by regular measuring of the blood pressure of pregnant women. This is possible if women
regularly attend antenatal care. Development of the symptoms signifies that the disease has
progressed to the severe form, previously called imminent eclampsia. These symptoms include
headache, epigastric or right hypochondriac pain, nausea, vomiting and visual disturbance If
pre-eclampsia is not treated, it can progress to eclampsia.
Pre-eclampsia can be classified into mild or severe forms. All cases that were previously termed
imminent eclampsia are now put under severe pre-eclmapsia.
Feature

Mild pre-eclampsia

Severe pre-eclampsia

Diastolic Blood 90-109 mmHg
Pressure

>110mmHg and above

Symptoms

Little or none

Development of symptoms

Proteinuria

2+ or less

3+ or more

Symptoms of severe pre-eclampsia (previously known as imminent eclampsia) are as
follows:
•
Headache
•
Visual disturbances
•
Epigastric or right hypochondrial pain
•
Nausea and vomiting

Other features of severe pre-eclampsia are as follows:
•
Oligouria: <400mls of urine in 24 hours
•
Intrauterine growth retardation
•
Deranged liver function tests
•
High serum uric acid and creatinine
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•
HELLP syndrome: Haemolysis, elevated liver enzymes and low platelets
•
Thrombocytopenia <50,000/ml
•
Hypereflexia
•
Generalized oedema
•
Pulmonary oedema

Prevention of pre-eclampsia
The exact aetiology of pre-eclampsia is not known, thus it has been difficult to develop
interventions that can provide absolute prevention. There are many interventions in literature,
but the ones that have shown some promise are:
1.
Low-dose Aspirin
75mg is given daily to the woman with risk factors for developing pre-eclampsia as early as 12
weeks gestation and is continued until 36 weeks gestation. It has the best evidence so far
amongst the options available.
2.
Calcium supplement
2gm daily of supplemental calcium has been used for women at risk of pre-eclampsia at
gestational age of 13-21 weeks with beneficial outcomes.

Trainees' Notes:
GROUP WORK
Trainees to be distributed into two groups of group A and B
i.

GROUP A: Demonstrate how to take the blood pressure of a pregnant
woman using the sphygmomanometer.

ii. GROUP B: Demonstrate how to check for proteinuria in the urine of a
pregnant woman, using the urine test strip and the sample provided.

1
2

Hoffmeyr GJ, Atallah AN, Duly, 2006
Villar et al 2006
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SESSION 2:
DIAGNOSIS OF ECLAMPSIA

OBJECTIVES
At the end of this session participants will be:
1.
2.
3.
4.

Know how to diagnose eclampsia
Know the differential diagnosis of eclampsia
Identify complications of eclampsia
Know how to prevent eclampsia

METHODOLOGY
?
Lecture
?
Group work
?
Brainstorming
?
Practical demonstration
RESOURCE
?
Flip chart/markers
?
Sphygmpmanometer/stethoscopes
?
Power point projector
?
Text books
?
Instructional materials

DURATION
45 minutes
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CONTENT
DEFINITION/DIAGNOSIS
Eclampsia is the occurrence of generalized convulsions (fits) in a pregnant woman with preeclampsia.
The convulsions may occur in pregnancy after 20 weeks of gestation, during labour or
pueperium commonly within the first 48 hours. It usually complicates pre-eclampsia but can
occur in some cases without prior clinically detected pre-eclampsia. Not all cases follow an
orderly progression from mild to severe disease and some women may develop eclampsia
suddenly.
The symptoms of eclampsia are generalised tonic-clonic convulsions that may be associated
with loss of consciousness, faecal and urinary incontinence. It is similar to an epileptic fit. It
can be antepartum (before onset of labour), intrapartum (during labour) or postpartum
(after delivery).
The stages of the fits are as follows:
Premonitory stage: lasts 10-20 seconds and characterised by
•
Rolling of the eyes
•
Facial and hand muscle twitching
Tonic stage: lasts about 30 seconds and characterised by
•
Muscle spasm
•
Clenching of the fists and teeth
•
Spasm of the diaphragm which may stop breathing and leading to cyanosis
•
Bulging of the eyes
Clonic stage: lasts 1-2 minutes and characterised by
•
Violent contractions of the muscles
•
Facial congestion and foaming at the mouth
•
Noisy breathing
Coma stage: lasts for minutes or hours and characterised by
•
deep unconsciousness with noisy breathing
•
Further fits may occur
In real life situations, events occur so rapidly that the most obvious stage is the
clonic phase where there are violent contractions of the muscles (fits).
RELEVANT INVESTIGATIONS
The following investigations should be conducted:
•
Full blood count, grouping and cross-matching
•
Urinalysis (protein, sugar and acetone)
•
Liver function test
•
Urea, electrolyte and creatinine
•
Urea, electrolyte and creatinine; Serum uric acid
DIFFERENTIAL DIAGNOSIS
The following are differential diagnosis:
•
Epilepsy
•
Meningitis
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•
Cerebral malaria
•
Electrolyte imbalance; Hypo/hyperglycaemia
•
Hypertensive stroke; Head trauma; cerebral tumours, drug overdose
COMPLICATIONS
The complications of eclampsia are maternal and foetal.
Maternal:
•
Respiratory problems (Pulmonary Oedema, Broncho-Pneumonia)
•
Renal complications (Acute renal failure)
•
Cerebral oedema, thrombosis or haemorrhage
•
Heart failure and Liver rupture
•
HELLP syndrome (haemolysis, elevated liver enzymes, low platelet count)
•
Clotting and Coagulation failure
•
Visual impairment (e.g. blurring, blindness)
•
Physical injuries/fractures during convulsions
•
Maternal death
Foetal:
•
Birth Asphyxia
•
Jaundice
•
Prematurity
•
Intrauterine growth retardation ( IUGR)/Still birth
•
Still birth (due to placental insufficiency)
•
Intrauterine foetal death (IUFD)
Prevention of pre-eclampsia and eclampsia
•
Focused antenatal care to detest early signs of pre-eclampsia and early treatment
•
Improving the referral system (early referral)
•
Access to skilled and motivated health personnel
•
Access to appropriate drugs and supportive care
•
Awareness creation on importance of antenatal care and identification of danger signs of
pre-eclampsia
•
Improving literacy level
•
Eradicating poverty and empowering women socio economically
•
Involvement of other stakeholders (community and religious leaders) in the management
of pre-eclampsia and eclampsia
?
Overcoming the three models of delays in obstetrics: delay at home in deciding to seek
treatment, delays in reaching a health facility and delay in receiving care at the health
facility

Trainee's Notes: GROUP WORK
In assigned groups, appoint a group leader to facilitate and a note taker to present
the group report.
The groups should brainstorm on “how eclampsia can be prevented in our
communities”
Document your notes in the flipchart sheet provided.
Present work to the larger group

19

SESSION 3:
TREATMENT OF PRE-ECLAMPSIA
OBJECTIVES
At the end of this session participants will be able to:
1. Know the principles of treatment of pre-eclampsia
2. Know the antihypertensive and anticonvulsant drugs in the treatment of pre-eclampsia
3. Know the modes of delivery for women with pre-eclampsia
METHODOLOGY
•
Lecture
•
Group work
•
Brainstorming
•
Bedside practical demonstration
RESOURCE
•
Flip chart & markers
•
Sphygmomanometer/stethoscopes
•
Power point projector
•
Text books
•
Instructional materials
DURATION
45 minutes
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CONTENT
The principles of treatment are as follows:
1. Controlling the hypertension
2. Prevention of convulsions
3. Delivery of the foetus
1. Controlling the hypertension
Drugs are used to control the blood pressure with the aim of achieving or maintaining a diastolic
blood pressure of 90-100mmHg.
Mild pre-eclampsia can be treated on outpatient basis, while severe pre-eclampsia will require
hospital admission.
The following classes of antihypertensive drugs can be used in controlling hypertension:
•
Vasodilators (e.g. Hydrallazine) - This is used when the diastolic blood pressure is
110mmHg or more. It is a rapid acting vasodilator. It is given at a dose of 10mg given
intravenously (IV) slowly over 5-10 minutes. It may to be repeated after 30 minutes if the
diastolic blood pressure remains more than 100mmHg.
The side effects include headache, dizziness, hypotension and collapse (common if the
drug is administered rapidly)
•
Centrally acting antihypertensive (e.g. methyldopa) - This is the preferred long-term oral
antihypertensive agent in pregnancy. Its safety in pregnancy has been established and
no serious fetal side effect has been documented. The dose is 250mg given orally three
times a day although the dose can be increased up to a maximum dose of 4g in 24 hours
in order to achieve the desired blood pressure.
Its side effects of alpha methyl-dopa include sedation, tiredness and postural
hypotension
•
Calcium channel blockers (e.g. Nifedipine) - The drug can be used orally or sublingually. It
has a rapid onset of action of 10-15 minutes. The daily dose is 20mg, which can be
increased to a maximum daily dose of 120mg. The side effects include headache,
hypotension and dizziness.
•
Other antihypertensive drugs that can be used include labetalol and verapamil.
2. Prevention of convulsions
In severe pre-eclampsia, there is need to use anticonvulsants to prevent the progression of the
condition to eclampsia. Previously diazepam was used for this purpose. It has however been
confirmed that magnesium sulfate is the best drug for this purpose. Magnesium sulfate should be
used to treat women with severe pre-eclampsia as discussed under the session for the treatment
of eclampsia.
3. Delivery of the foetus
Where the foetus is matured (37 weeks of gestation or more), in a patient with pre-eclampsia,
immediate delivery is advised. This is usually by induction of labour. However, other obstetric
indications (e.g. associated intrauterine growth restriction) may be considered and the patient
offered elective caesarean section.
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For gestational ages less than 37 weeks of gestation, conservative treatment could be offered
provided the pre-eclampsia is mild. Once the gestational age of 37 weeks is achieved, the patient
should be delivered.
Conservative treatment involves the following:
•
Bed rest
•
Fetomaternal monitoring: maternal blood pressure monitoring, foetal kick chart, CTG
(cardiotocography) (non-stress test) as appropriate and twice weekly biophysical profile
(where available)
•
Regular investigations: daily urinalysis, twice weekly urea, electrolyte, creatinine, uric
acid and liver function test estimations
It should be noted however that a patient with mild pre-eclampsia may suddenly progress to
severe pre-eclampsia or even eclampsia, in which case the management will change
appropriately.
In severe pre-eclampsia, where the gestational age is equal to or more than 34 weeks,
immediate delivery is advised. Where the gestational age is less than 34 weeks, the risk of the
delivery should be weighed against the maternal benefit.
With delivery of the baby and placenta, there is usually an improvement in the clinical condition
of the mother.
Note: avoid the use of ergometrine after delivery as it can cause a further rise in the blood
pressure. Rather, syntocinon can be given 10 IU IM stat.

Learner's Note:
GROUP WORK
Divide into two groups of A and B.
Group A shall answer Question 1 (use flipchart sheets to write answers)
1. What are the principles of treatment of pre-eclampsia?
while Group B shall answer Question 2 (use flipchart sheets to write answers)
2. Name three common drugs used in the treatment of pre-eclampsia
PRACTICAL SESSION: BED SIDE TEACHING
Both groups should demonstrate the administration of Hydrallazine using the syringe and
needle provided
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SESSION 4
TREATMENT OF ECLAMPSIA
OBJECTIVES
At the end of this session participants should be able to:
1.
2.
3.
4.
5.

Know
Know
Know
Know
Know

the
the
the
the
the

principles of treatment of eclampsia
early resuscitative measures used in the treatment of eclampsia
regimen of the antihypertensives and anticonvulsants used in treating eclampsia
modes of delivery for women with eclampsia
post partum care of eclampsia

METHODOLOGY
•
Lecture
•
Group work
•
Brainstorming
•
Bedside practical demonstration
RESOURCE
•
Flip chart & markers
•
Sphygmomanometer/stethoscope
•
Power point projector
•
Text books
•
Instructional materials
DURATION
60 minutes
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CONTENT
Eclampsia can be antepartum, intrapartum or postpartum (refer to session on diagnosis of
eclampsia).
The principles of management are as follows:
1.
2.
3.
4.
5.
6.
7.

Resuscitation
Controlling the fits
Controlling the blood pressure
fluid and electrolyte balance
Nursing care
delivery of the baby
post delivery care to prevent further fits and other complications

1. Resuscitation
It is important to resuscitate the patient as follows:
• position patient in left lateral position away from harmful objects
• Clear and maintain airway (insert oropharyngeal airway and suction when necessary)
• Give oxygen by face mask
• Pass NG tube and indwelling Foley's catheter (take urine specimen to check for protein)
• Set up an intravenous infusion and take blood samples for investigations
• Take brief history and determine the patient's blood pressure
• If in a primary health facility, refer the patient to a higher facility for further care
2. Control of fits
Several agents can be used to control fits in eclampsia. These include diazepam, phenytoin,
paraldehyde, 'lytic cocktail' and magnesium sulfate. However, the best agent for this is
magnesium sulfate.
There are principally two main regimens (Pritchard and Zuspan) for the administration of MgSO4.
Others like Dhaka and Sokoto 'ultrashort protocols are not popular yet.
In the Pritchard Regimen, the loading dose is MgSO4 4g bolus given slowly intravenously over 510 minutes and this is followed by 10gm given intramuscularly (5g in each buttock).
Subsequently, 5g is given IM four-hourly in alternate buttocks. This is the preferred regimen in
Nigeria.
In the Zuspan regimen, the loading dose consists of an initial intravenous dose of 4g slowly over
5-10 minutes followed by a maintenance dose of 1-2g hourly given by an infusion pump. A
gravity fed infusion set can be used in the absence of the pump especially in the developing
countries.
Note that for the 50% MgSO4, 1 ml of the solution contains 0.5g of MgSO4 while for the 20%
solution; 1 ml contains 0.2g of MgSO4. There is need to dilute the initial intravenous loading dose
if the 50% solution is been used to 20% solution to avoid vascular irritation. This is done by
diluting 8mls (4g) of the 50% solution to 20mls using a 20ml syringe. The commonly used
diluents are 5% dextrose water, normal saline or water for injection (using a 20ml syringe).
3

Belumet al, 2001
Ekele et al, 2009
5
FMOH, 2009
4
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Monitoring is important to ensure that the right doses are administered and this is not an easy
task. Whatever regimen chosen, the drug should be administered for 24 hours after delivery or
after the last fit (whichever comes last). If convulsions recur, give an extra 2 g of MgSO4 IV over
five minutes
Toxicity of the drug should be monitored using the following clinical parameters;
• the knee jerk (should be present)
• respiratory rate (should be more than 16 per minute)
• Urine output (should be more than 30 ml per minute).
The first warning sign of toxicity is loss of the knee jerk.
In case of toxicity:
•
•
•

Stop the drug
Support respiration with ambu bag and oxygen/ventilator
Administer the antidote which is 1g of 10% Calcium gluconate given intravenously slowly
over 10 minutes.

3. Controlling the blood pressure
If diastolic blood pressure is equal to or more than 110mmHg, administer IV hydrallazine 10mg
slowly over 5-10 minutes. The aim is to reduce and maintain the diastolic blood pressure below
110mmHg. Where the blood pressure cannot be controlled by repeated boluses of Hydrallazine,
the drug may be put into the infusion and titrated against the blood pressure at the rate of 1mg
per minute.
This can be administered by putting 40mg of Hydrallazine in 500mls of normal saline in the
infusion/infusion pump to run over 4 hours (1-5mg per hour)
4.

Correct fluid and electrolyte imbalance

Eclamptic patients have a contracted blood volume. Fluid replacement should be with care. The
best recommended intravenous fluid is Ringers Lactate administered at the rate of 1L every 8
hours. Where it is not available, other fluids such as normal saline, 5% dextrose water or
dextrose saline could be used. Electrolytes may need to be corrected depending on the result of
the serum urea and electrolyte.
5. Nursing care
The patient should ideally be nursed in the intensive care unit (ICU) or high dependency area
(HDA). Nursing care will involve the following:
• Nurse in a cool quite environment
• Regular turning of the patient every 30 minutes
• Care of the pressure areas to avoid bed sores
• Regular vital signs monitoring
• Catheter care
• Infection prevention
6. Delivery of the baby
After stabilization, eclamptic patients should be FULLY examined, which ideally should include
the following:
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•
•
•
•

General physical examination
Vital signs: pulse rate, blood pressure, respiratory rate, temperature and urine output
Examination of the cardiovascular, respiratory, central nervous and the abdomen
Pelvic examination to determine if the patient is in labour

After the examinations are completed, delivery of the patient should be planned. Vaginal
delivery is the route of choice, and the labour could be augmented to speed up the delivery. The
second stage should be assisted preferably by forceps or vacuum can also be used.
However, if the delivery is not feasible in the next 6-8 hours, caesarean section is recommended.
With delivery of the baby and placenta, there is usually an improvement in the clinical condition
of the mother. Avoid the use of ergometrine after delivery as it can cause a further rise in the
blood pressure. Rather, syntocinon can be given 10IU IV stat and 40 IU added to 500mls
dextrose/saline infusion to run over 4 hours
7. Post delivery care to prevent further fits and other complications
It is important to continue the maintenance doses of intravenous fluids, anticonvulsant and
antihypertensives (where indicated). The nursing care should be continued. As the patient
recovers, oral feeding can be commenced within 24 to 48 hours. At that point, oral
antihypertensive drugs can be introduced (as described under the session for treatment of preeclampsia). The patient can be discharged after full recovery of consciousness and stabilization
of the blood pressure.
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EXAMPLE OF A MANAGEMENT PROTOCOL

General measures
•
Call for help;
•
Maintaining a patent airaway: insert oropharyngeal tube and suction PRN
•
Support breathing (Oxygen administration) and if not breathing: assist ventilation with ambu
bag or perform intubation
•
Monitor vital signs: BP, temperature, respiration
•
Catheterise bladder; Monitor fluid input and output
•
Full blood count, grouping and cross-matching, Urine analysis, Random blood sugar

Control of fits (Use of Pritchard regime)
•
MgSO4 4gm IV bolus over 5-10 minutes (loading dose)
•
Additional MgSO4 of 10g (5g in each buttock IM)
•
If convulsions recur after 15 minutes, give 2 g of MgSO4 IV over five minutes
•
Maintain with 5g IM 4hrly in alternate buttocks for 24hrs after delivery or for 24 hours
after the last fit (whichever comes last)
•
Put patient in left lateral position;
Monitor for MgSO4 toxicity
•
Patella deep tendon reflex should be present (first to go if there is toxicity)
•
Respiratory rate should be > 16/min
•
Urine output should be >30ml/hour
•
Administer 1g of 10% Calcium gluconate IV (slowly over 5-10 minutes) if there is evidence of
magnesium sulphate toxicity
Control BP:
If diastolic BP > 110: 10 mg Hydrallazine slowly IV (in 5 minutes);
then 5 mg iv every 30 minutes until diastolic BP <100mmHg
Fluid management:
Limit fluid intake to 1L 12 hourly (2litres in 24 hours)

Deliver the baby within 6-9 hours:
- If not in labour: Caesarean section
- If in labour: consider augmentation of labour and shorten 2nd stage with forceps or vacuum
extraction;
•
Avoid ergometrine after delivery; rather use syntocinon 10 IU IM stat.

Consider other measures like:
Anti-malarial
Antibiotics
Antipyretics
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Follow up
The patient should be reviewed in the post natal clinic within a week after discharge. She should
be asked and investigated (verbally and physically) for any complaints. Her vital signs especially
the blood pressure should be measured. Oral antihypertensive drugs may need to be continued
for some time if the blood pressure remains high.
The patient should be educated on the cause of the condition and how it could be prevented in
subsequent pregnancy. The importance of antenatal care should be emphasized especially as
there is risk of recurrence of the condition. Contraception should be offered.
At the six-week post natal visit, the patient should be referred to the physician if the blood
pressure remains high.
Management of some common complications of Eclampsia
• Acute Renal Failure:
Renal challenge with frusemide
Fluid restriction (maintain with previous days output and insensitive loss)
Monitor Input and Output
Monitor and correct Electrolyte, Urea, Creatinine
Give antibiotics
Dialysis
• Aspiration Pneumonitis
Antibiotics
Chest physiotherapy
Steroids and oxygen in severe cases
Controlled ventilation in the ICU
• Hyperpyrexia
Nurse in a cool environment
Tepid sponge
Antipyretics

Trainees' Notes: BED SIDE TEACHING
The group may be divided into three groups A, B & C.
Each of the group shall demonstrate one of the tasks mentioned below:
•
Demonstrate resuscitation in the eclamptic patient who has just been
presented to the health facility
•
Administer magnesium sulfate with the drug in the syringe provided
•
Demonstrate the use of patella hammer to check for knee reflex with the
patella hammer provided
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(1) PHARMACOLOGY OF
MAGNESIUM SULFATE

SESSION

4. Know the common side
effect and toxicity of
magnesium sulphate.

3. Know the dosage and the
route of administration of
magnesium sulphate

2. Know the clinical indication
for the use of magnesium
sulphate

1. Know the physiological roles
and mechanism of action of
magnesium sulphate

OBJECTIVES

?
Brainstorming

•
Discussion

•
Lecture

METHODOLOGY/
ACTIVITY

CASE STUDIES

MODULE 3

•
Text books

•
Power point
projector

•
Flip charts/stand
and markers

RESOURCES

1 hours

E TIME
FRAME

PHARMACOLOGY OF MAGNESIUM SULPHATE
OBJECTIVES
At the end of this session participants should be able to:
1.
2.
3.
4.
5.

Know
Know
Know
Know
Know

the
the
the
the
the

physiological role and the and mechanism of action of magnesium sulphate
clinical indication for the use of magnesium sulphate
dosage and the route of administration of magnesium sulphate
contra-indications and precautions for the use of magnesium sulphate
common side effects and toxicity of magnesium sulphate.

METHODOLOGY
•
Lecture
•
Discussion
RESOURCE
•
Flip chart & markers
•
Power point projector
•
Text books
•
Instructional materials
DURATION
1 hours
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CONTENT
1. Clinical pharmacology and mechanism of action of magnesium sulphate
2. Indications for the use of magnesium sulphate
3. Dosage and route of administration including clinical indication for the use of magnesium
sulphate
4. Contraindications and precautions for the use of magnesium sulfate
5. Side effects and toxicity of magnesium sulphate

1. Clinical pharmacology/Mechanism of action
•
Magnesium [Mg2+] is an important cofactor for enzymatic reactions and plays an important
role in neurochemical transmission and muscular excitability.
•
The mechanism of action of magnesium sulfate is not completely understood.
•
Magnesium sulphate acts peripherally to produce vasodilatation
•
It controls convulsions by blocking N methyl D-aspartate receptors (NMDA) centrally
•
It is also thought to displace calcium at the neuro-muscular endplate thereby inhibiting
neuromuscular transmission.
•
Magnesium is said to have a depressant effect on the central nervous system

2. Dosage and administration / clinical indication
Dosage and administration
•
Magnesium sulfate can be administered either intravenously or intramuscularly; however the
regimen used, initial dose is intravenous.
- Intramuscular regime (Pritchard):
The loading dose is 4g bolus given slowly intravenously over 5-10 minutes, and this is followed by
10g intramuscularly [5g into each buttock]. Subsequently 5g is given intramuscularly four hourly
in alternate buttocks
- Intravenous regimen (Zuspan):
The loading dose consist of an initial intravenous dose of 4g given slowly over 5-10 minutes,
followed by a maintenance dose of 1-2g hourly
Whatever the regimen chosen, the drug should be administered till 24 hours after delivery or
after the last fit; although the optimal length of treatment is not established. Other protocols like
Dhaka and Sokoto (ultra-short) regimens are not popular yet.
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3.

Clinical indications:
•
Parenteral administration of magnesium sulphate is indicated for prevention and control
of convulsions in the treatment of severe pre-eclampsia and eclampsia respectively.
•
Magnesium sulphate can be used as tocolytic agent in the management of preterm
labour.
•
Magnesium sulphate injection can also be used in the control of hypertension,
encephalopathy and convulsions associated with acute nephritis in children.

4. Contraindications/ Side effect
Contraindications:
Magnesium sulphate should not be administered parenterally in patients with heart block or
myocardial damaged. Caution should be exercised in patients with impaired renal function and
in the presence of electrolytes imbalance.
5. Side effect:
Adverse effects of parenterally administered magnesium sulphate include flushing, sweating,
hypotension, depressed reflexes, flaccid paralyses, gastro-intestinal disturbance (diarrhoea,
abdominal distention) urinary retaintion, hypothermia, circulatory collapse, cardiac and CNS
depression (central sedation, decreased excitability) proceeding to respiratory paralysis.
Hypocalcaemia with signs of tetany may occur.

6. Symptoms and treatment magnesium sulphate toxicity
Disappearance of the patella reflex is the first sign to detect the onset of magnesium
intoxication. The next is respiratory depression followed by cardiac arrest. In the event of over
dosage, artificial ventilation must be provided until a calcium salt can be injected intravenously
to antagonize the effect of magnesium.
In adults, intravenous administration of 10mls of 10% calcium gluconate slowly over 10
minutes will usually reverse respiratory depression or heart block due to magnesium
intoxication. In extreme cases, peritoneal dialysis or haemodialysis may be required.

Trainees's Note:
1. Ask questions or seek clarifications
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(1) CASE STUDIES

SESSION

5. Explain the importance of
reflecting on practice in order
to evaluate and improve care.

4. Describe how improved
maternity care can influence
the outcome of the
management of eclampsia and
pre-eclampsia, giving
examples from experience.

3. Discuss how other women may
also benefit from aspects of
care which contributed to a
safe outcome or lessons
learned from a poor outcome.

2. Identify the process which led
to the outcome of the case
studied, emphasizing the
important points of practice in
the prevention and
management of eclampsia.

1. Present a case study and
discuss the important
questions relating to it.

OBJECTIVES

•
Discussion
Group work

•
Case studies

METHODOLOGY/
ACTIVITY

CASE STUDIES

MODULE 4:

Managing eclampsia.
Educational material for
teachers of midwifery.
WHO Midwifery
education module second edition

RESOURCES

2 hours

TIME

CASE STUDIES
OBJECTIVES
At the end of this session participants should be able to:
1. Present a case study and discuss the important questions relating to it.
2. Identify the process which led to the outcome of the case studied, emphasizing the
important points of practice in the prevention and management of eclampsia.
3. Discuss how other women may also benefit from aspects of care which contributed to
a safe outcome or lessons learned from a poor outcome.
4. Explain the importance of reflecting on practice in order to evaluate and improve
care.
METHODOLOGY
• Case studies
• Discussion
• Group work
RESOURCE
•
Flip chart & markers
•
Handouts
•
Instructional materials
DURATION
2 hours

Trainee's Notes:
Read the following case studies carefully and answer the accompanying questions.
Preferably, this be done as group work
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CONTENT
Case studies
Case 1:
Mrs. X was a 16 year old primigravida reported to the primary health care centre in her village at
eight month of pregnancy when she developed severe headache. The community health
extension worker [CHEW] that received her could only check her blood pressure which was
150/110mmHg, and performed abdominal examination. She made a diagnosis of hypertension,
gave her aldomet tablets 250mg twice daily for one week and asked her to return for follow up a
week later.
Two days later Mrs.X came back with the complaint of severe headache and inability to see very
well. Few minutes later she started convulsing.

1. Comment on the diagnosis made by the CHEW and the treatment given.
2. What is the most likely diagnosis and why?
3. How best would you have managed Mrs. X?

Case 2:
A 23-year-old, primigravida at 36 weeks gestation, was brought to the hospital with history of
convulsions. She had 2 episodes at home and 2 on the way to the hospital. On admission she was
not pale but had bilateral pitting pedal oedema. Her blood pressure was 160/110 mmHg. A single
fetus in cephalic presentation and normal fetal heart rate were the findings on abdominal
examination. Pelvic examination confirmed a 6cm cervical dilatation with adequate pelvis On
pelvic examination her cervix was 6cm dilated, cephalic presentation. Urinalysis revealed 2+ of
proteinuria.
1.
2.

How would you manage this patient
What difficulties would you have had managing this patient in your centre

Case 3
An 18year old primigravida was referred from a primary health care facility at 38 weeks gestation
having convulsed twice at home. She was unconscious; her blood pressure was 170/120mmHg.
She had 10mg of diazepam intravenously and 40mg in 500mls of normal saline.
She had four further episodes of convulsions before referral. At the referral hospital, she was
given Parenteral Magnesium sulphate which controlled her convulsions. She was also placed on
antihypertensive.
At vaginal examination, cervical os was 7cm dilated and membranes were intact with adequate
pelvis. Samples were taken for full blood count, liver function test, electrolyte, urea and uric acid,
and urinalysis.
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She had artificial rupture of membranes. Three hours later, she had assisted delivery of a live
baby boy with a low Apgar scores. She regained consciousness 72 hours after admission but
continued to have impaired vision.

1. Why did she continue to have recurrent convulsions at the primary health care facility?
2. At the referral hospital, what abated (stopped) the convulsions?
3. Comment on the possible cause of slow recovery (unconsciousness for 72 hours) and
impaired vision this patient had.
4. Why did you think the baby had low Apgar scores?

Case Four
Sister Florence was the only midwife on night duty assisted by one CHEW when a 22year old
unbooked primigravida was brought into the labour ward unconscious. She had fitted 4 times at
home. She was given traditional medications because her illness was believed to be due to evil
spirit. She convulsed twice on the way to the hospital. Her husband said she was 9months
pregnant and had enjoyed good health until 2days ago when she complaint of progressive leg
swelling, chest pain, and then the first episode of convulsion. She has not passed urine since the
previous day.
Sister Florence gave the patient the only remaining 10mg of diazepam available when she began
to convulse again.
The midwife recorded a blood pressure of 140/100mmHg and performed pelvic examination and
confirmed she was not in labour after which she made a diagnosis of ante partum eclampsia. The
midwife referred the patient to the nearby General hospital that was 60km away. The patient was
still at the primary health care facility 2hours after the referral due to transportation problem
when suddenly started gasping and died 30 minutes later despite resuscitative measures.
1. What was the probable cause of death and what factors contributed to the death?
2. What were the challenges in giving live saving management?
3. What should be done in order to avoid these problems in the future?
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